Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthes Bone Void Filler Off-Label Concerns, MDR Gaps Elicit FDA Warning

This article was originally published in The Gray Sheet

Executive Summary

Synthes should have secured an investigational device exemption before soliciting information from physicians on patient experiences with the firm's Norian XR calcium phosphate bone void filler, according to a recent FDA warning letter

You may also be interested in...



Synthes Charged With Unauthorized Spine Repair Trial, Faces $34 Mil. Fine

Orthopedic device maker Synthes and its Norian subsidiary face $34.8 million in potential fines for allegedly skirting FDA requirements and conducting unauthorized clinical trials of their Norian XR and Norian SRS bone cement for vertebral compression fractures

Synthes Charged With Unauthorized Spine Repair Trial, Faces $34 Mil. Fine

Orthopedic device maker Synthes and its Norian subsidiary face $34.8 million in potential fines for allegedly skirting FDA requirements and conducting unauthorized clinical trials of their Norian XR and Norian SRS bone cement for vertebral compression fractures

SYNTHES SPINAL INSTRUMENT PROCESS VALIDATION GMP DEFICIENCIES

SYNTHES SPINAL INSTRUMENT PROCESS VALIDATION GMP DEFICIENCIES result in receipt of a warning letter from FDA. Following inspections of the company's Exton and Paoli, Pennsylvania facilities conducted Aug. 9-26, the agency concluded in the Sept. 23 letter that the company's process validation procedures are not "adequate to assure product integrity."

Related Content

UsernamePublicRestriction

Register

MT021425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel